1-11 of 11
Todd Busman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Free
William G Wierda, MD PhD, John F Seymour, MBBS, PhD, Andrew W. Roberts, Su Young Kim, L. Leanne Lash-Fleming, Johnathan Maher, Todd Busman, Lang Zhou, Jacqueline Nielsen, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4329.
https://doi.org/10.1182/blood.V130.Suppl_1.4329.4329
Published: 2017
Journal Articles

Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia

Free
John F Seymour, Matthew S. Davids, Andrew W. Roberts, Michael Hallek, William G. Wierda, MD PhD, Peter Hillmen, John F. Gerecitano, Elisa Cerri, Jalaja Potluri, Su Young Kim, Todd Busman, Maria Verdugo, Rod A. Humerickhouse, MD, Andrea Best, Monali Desai, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 4395.
https://doi.org/10.1182/blood.V128.22.4395.4395
Published: 2016
Journal Articles

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Free
Jeffrey Jones, MD, Anthony R. Mato, MD, Steven Coutre, MD, William Wierda, MD PhD, Michael Y. Choi, MD, Matthew S. Davids, MD, Nicole Lamanna, MD, Paul Barr, MD, Kim Burns, BA, Nicholas Montalvo, MBA, Ming Zhu, PhD, Todd Busman, MS, Jalaja Potluri, MD FACP, Rod A. Humerickhouse, MD PhD, John C. Byrd, MD
Journal: Blood
Blood (2015) 126 (23): 715.
https://doi.org/10.1182/blood.V126.23.715.715
Published: 2015
Journal Articles

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Free
Marina Konopleva, MD PhD, Daniel A. Pollyea, MD MS, Jalaja Potluri, MD, Brenda J. Chyla, PhD, Todd Busman, MS, Evelyn McKeegan, PhD, Ahmed Salem, PhD, Ming Zhu, PhD, Justin L. Ricker, MD PhD, William Blum, MD, Courtney D. DiNardo, MD, Martin Dunbar, DRPH, Rachel Kirby, Nancy Falotico, Joel D. Leverson, PhD, Rod A. Humerickhouse, MD PhD, Mack Mabry, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Anthony G. Letai, MD PhD
Journal: Blood
Blood (2014) 124 (21): 118.
https://doi.org/10.1182/blood.V124.21.118.118
Published: 2014
Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Free
Thomas J. Kipps, M.D., Ph.D, Lode J. Swinnen, MD, William G. Wierda, MD, PhD, Jeffrey Alan Jones, MD, MPH, Steven E. Coutre, MD, Mitchell R Smith, MD, PhD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2011) 118 (21): 3904.
https://doi.org/10.1182/blood.V118.21.3904.3904
Published: 2011
Journal Articles

Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

Free
Brad Kahl, MD, Andrew W Roberts, MBBS, PhD, John F Seymour, MD, Ranjana H. Advani, MD, Daniel Oscar Persky, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2010) 116 (21): 3943.
https://doi.org/10.1182/blood.V116.21.3943.3943
Published: 2010
Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Free
Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Lode J. Swinnen, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2010) 116 (21): 2455.
https://doi.org/10.1182/blood.V116.21.2455.2455
Published: 2010
Journal Articles

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Free
Wyndham H Wilson, MD, PhD, Owen A O'Connor, MD, PhD, Myron S Czuczman, Ann LaCasce, MD, John Gerecitano, MD, PhD, John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 1711.
https://doi.org/10.1182/blood.V114.22.1711.1711
Published: 2009
Journal Articles

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Free
Andrew W. Roberts, MBBS, PhD, John F Seymour, MB, BS, PhD, FRACP, Jennifer R Brown, MD, PhD, William G Wierda, Thomas J. Kipps, MD, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Hao Xiong, Ph.D., Yue Cui, PhD, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 883.
https://doi.org/10.1182/blood.V114.22.883.883
Published: 2009
Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Free
Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3177.
https://doi.org/10.1182/blood.V112.11.3177.3177
Published: 2008
Journal Articles

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Free
Wyndham H Wilson, MD, PhD, O. O’Connor, M.D., Myron S. Czuczman, MD, Ann LaCasce, MD, J. Gerecitano, M.D., Ph.D., John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Ph.D., Todd Busman, Ph.D., Raymond A. Knight, MBA, Sari Enschede, M.D., Andrew Krivoshik, M.D., Ph.D., Rod Humerickhouse, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 2108.
https://doi.org/10.1182/blood.V112.11.2108.2108
Published: 2008